IBM (NYSE:IBM) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 16,946,800 shares, an increase of 12.0% from the June 15th total of 15,127,300 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average daily trading volume, of 3,430,000 shares, the short-interest ratio is presently 4.9 days.

IBM traded up $0.97 during trading on Friday, hitting $151.36. The company had a trading volume of 2,904,285 shares, compared to its average volume of 3,749,706. The company has a market cap of $134.20 billion, a P/E ratio of 10.96, a PEG ratio of 2.58 and a beta of 1.25. The stock has a 50-day moving average of $140.75. The company has a current ratio of 1.83, a quick ratio of 1.79 and a debt-to-equity ratio of 3.51. IBM has a 1-year low of $105.94 and a 1-year high of $154.36.

IBM (NYSE:IBM) last posted its quarterly earnings results on Wednesday, July 17th. The technology company reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.11. The firm had revenue of $19.20 billion for the quarter, compared to analysts’ expectations of $19.20 billion. IBM had a net margin of 11.22% and a return on equity of 69.56%. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the company posted $3.08 earnings per share. Sell-side analysts predict that IBM will post 13.89 earnings per share for the current year.

A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of HANNOVER RUECK/S from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Tigress Financial reissued a “hold” rating on shares of IBM in a research report on Friday. JPMorgan Chase & Co. cut shares of News from a “neutral” rating to an “underweight” rating in a research report on Thursday, July 18th. BMO Capital Markets assumed coverage on shares of Yelp in a research report on Wednesday, April 17th. They set an “outperform” rating on the stock. Finally, ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $155.65.

In other news, SVP Kenneth M. Keverian sold 2,227 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $135.15, for a total transaction of $300,979.05. Following the transaction, the senior vice president now directly owns 32,878 shares of the company’s stock, valued at $4,443,461.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Kenneth M. Keverian sold 2,083 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $132.00, for a total transaction of $274,956.00. Following the transaction, the senior vice president now directly owns 34,465 shares in the company, valued at $4,549,380. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,000 shares of company stock worth $940,430. 0.19% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. MUFG Securities EMEA plc raised its holdings in IBM by 44.8% in the fourth quarter. MUFG Securities EMEA plc now owns 216,780 shares of the technology company’s stock valued at $24,641,000 after acquiring an additional 67,055 shares in the last quarter. BB&T Corp increased its stake in IBM by 1.8% during the first quarter. BB&T Corp now owns 51,779 shares of the technology company’s stock valued at $7,306,000 after purchasing an additional 901 shares during the last quarter. Adell Harriman & Carpenter Inc. bought a new stake in IBM during the first quarter valued at $207,000. Greenleaf Trust increased its stake in IBM by 12.4% during the first quarter. Greenleaf Trust now owns 8,057 shares of the technology company’s stock valued at $1,137,000 after purchasing an additional 891 shares during the last quarter. Finally, Tibra Equities Europe Ltd bought a new stake in IBM during the first quarter valued at $4,797,000. 55.18% of the stock is currently owned by hedge funds and other institutional investors.

IBM Company Profile

International Business Machines Corporation operates as an integrated technology and services company worldwide. Its Cognitive Solutions segment offers a portfolio of enterprise artificial intelligence platforms, such as analytics and data management platforms, cloud data services, talent management, and industry solutions primarily under the Watson Platform, Watson Health, and Watson Internet of Things names.

Recommended Story: Earnings Per Share

Receive News & Ratings for IBM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IBM and related companies with MarketBeat.com's FREE daily email newsletter.